J Prendiville

1.6k total citations
40 papers, 1.3k citations indexed

About

J Prendiville is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, J Prendiville has authored 40 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 9 papers in Molecular Biology. Recurrent topics in J Prendiville's work include Lung Cancer Research Studies (11 papers), Lung Cancer Treatments and Mutations (8 papers) and Neuroendocrine Tumor Research Advances (7 papers). J Prendiville is often cited by papers focused on Lung Cancer Research Studies (11 papers), Lung Cancer Treatments and Mutations (8 papers) and Neuroendocrine Tumor Research Advances (7 papers). J Prendiville collaborates with scholars based in United Kingdom, United States and Czechia. J Prendiville's co-authors include Nicholas Thatcher, Peter L. Stern, D. Crowther, D Crowther, G. Walsh, Gordon C. Jayson, S. Johnston, Christof Scheid, David Cunningham and H Robertshaw and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

J Prendiville

39 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J Prendiville United Kingdom	19	743	373	240	215	176	40	1.3k
B Leyland-Jones United States	16	847 1.1×	418 1.1×	197 0.8×	214 1.0×	148 0.8×	42	1.7k
C.J.A. van Moorsel Netherlands	14	644 0.9×	445 1.2×	333 1.4×	141 0.7×	116 0.7×	16	1.1k
T Ohnuma United States	16	812 1.1×	554 1.5×	202 0.8×	104 0.5×	81 0.5×	40	1.7k
Catharina M. Kuiper Netherlands	16	936 1.3×	493 1.3×	306 1.3×	115 0.5×	93 0.5×	24	1.3k
Bristi Basu United Kingdom	21	817 1.1×	638 1.7×	249 1.0×	307 1.4×	139 0.8×	85	1.5k
Veronique W.T. Ruiz van Haperen Netherlands	15	784 1.1×	644 1.7×	238 1.0×	210 1.0×	69 0.4×	22	1.3k
D M Goldenberg United States	29	699 0.9×	563 1.5×	285 1.2×	91 0.4×	238 1.4×	85	2.1k
Ed Cadman United States	23	696 0.9×	555 1.5×	358 1.5×	151 0.7×	360 2.0×	58	1.6k
R. Gralla United States	15	1.1k 1.5×	427 1.1×	469 2.0×	95 0.4×	82 0.5×	38	1.9k
Emily Dunn United States	13	873 1.2×	741 2.0×	492 2.0×	220 1.0×	128 0.7×	24	1.7k

Countries citing papers authored by J Prendiville

Since Specialization

Citations

This map shows the geographic impact of J Prendiville's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J Prendiville with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J Prendiville more than expected).

Fields of papers citing papers by J Prendiville

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J Prendiville. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J Prendiville. The network helps show where J Prendiville may publish in the future.

Co-authorship network of co-authors of J Prendiville

This figure shows the co-authorship network connecting the top 25 collaborators of J Prendiville. A scholar is included among the top collaborators of J Prendiville based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J Prendiville. J Prendiville is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hughes, Simon, Aisha Miah, Shahreen Ahmad, et al.. (2008). A Brief Report on the Safety Study of Induction Chemotherapy Followed by Synchronous Radiotherapy and Cetuximab in Stage III Non-small Cell Lung Cancer (NSCLC): SCRATCH Study. Journal of Thoracic Oncology. 3(6). 648–651. 52 indexed citations

Paz‐Ares, Luis, Helen J. Ross, Mary O’Brien, et al.. (2008). Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. British Journal of Cancer. 98(10). 1608–1613. 125 indexed citations

Lee, Siow Ming, L. E. James, W. Qian, et al.. (2008). Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer. Thorax. 64(1). 75–80. 48 indexed citations

Hughes, Simon, Aisha Miah, Shahreen Ahmad, et al.. (2007). P2-184: Safety study of induction chemotherapy followed by Synchronous Radiotherapy (RT) and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study (Cohort I). Journal of Thoracic Oncology. 2(8). S642–S643. 1 indexed citations

Sedrakyan, Artyom, Jan van der Meulen, Kenneth J. O’Byrne, et al.. (2004). Postoperative chemotherapy for non–small cell lung cancer: A systematic review and meta-analysis. Journal of Thoracic and Cardiovascular Surgery. 128(3). 414–419. 4 indexed citations

Jodrell, Duncan I., T.R. Jeffry Evans, William P. Steward, et al.. (2004). Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma. European Journal of Cancer. 40(12). 1872–1877. 104 indexed citations

Lee, Siow Ming, et al.. (2002). A phase II study of carboplatin/etoposide with thalidomide in small cell lung cancer (SCLC). UCL Discovery (University College London). 13 indexed citations

Popescu, Răzvan, Andrew Wotherspoon, David Cunningham, et al.. (1999). Surgery plus chemotherapy or chemotherapy alone for primary intermediate- and high-grade gastric non-Hodgkin's lymphoma: The Royal Marsden Hospital experience. European Journal of Cancer. 35(6). 928–934. 23 indexed citations

McGown, Alan T., et al.. (1998). High-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique. Journal of Chromatography B Biomedical Sciences and Applications. 709(1). 113–117. 9 indexed citations

10.

Ross, Paul J., Andrew Webb, David Cunningham, et al.. (1997). Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: The Royal Marsden Hospital experience. Annals of Oncology. 8(2). 111–115. 6 indexed citations

11.

Weaver, Andrew, Gordon C. Jayson, Malcolm Ranson, et al.. (1996). A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: A comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals. Annals of Oncology. 7(7). 705–711. 16 indexed citations

12.

Jayson, Gordon C., D Crowther, J Prendiville, et al.. (1995). A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. British Journal of Cancer. 72(2). 461–468. 113 indexed citations

13.

Prendiville, J, Paul Lorigan, Frank D. Hicks, et al.. (1994). Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation. European Journal of Cancer. 30(14). 2085–2090. 10 indexed citations

14.

Anderson, Heather, Penelope Hopwood, J Prendiville, et al.. (1993). A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer. British Journal of Cancer. 67(6). 1385–1390. 23 indexed citations

15.

Murphy, Denis J., D. Crowther, J Prendiville, et al.. (1993). A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles. Annals of Oncology. 4(5). 377–383. 25 indexed citations

16.

Prendiville, J, D. Crowther, Nicholas Thatcher, et al.. (1993). A phase I study of intravenous bryostatin 1 in patients with advanced cancer. British Journal of Cancer. 68(2). 418–424. 129 indexed citations

17.

Prendiville, J, Nicholas Thatcher, Michael Lind, et al.. (1993). Recombinant human interleukin-4 (rhu IL-4) administered by the intravenous and subcutaneous routes in patients with advanced cancer—A phase I toxicity study and pharmacokinetic analysis. European Journal of Cancer. 29(12). 1700–1707. 36 indexed citations

18.

Murphy, Denis J., Michael Lind, J Prendiville, et al.. (1992). Phase study of intraperitoneal iproplatin in patients with minimal residual disease following platinum-based systemic therapy for epithelial ovarian carcinoma. European Journal of Cancer. 28(4-5). 870–872. 1 indexed citations

19.

Prendiville, J, John Radford, N. Thatcher, et al.. (1991). Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy.. Journal of Clinical Oncology. 9(8). 1446–1452. 24 indexed citations

20.

Anderson, H., J Prendiville, Nicholas Thatcher, John Radford, & R Swindell. (1991). A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer. Journal of Cancer Research and Clinical Oncology. 117(S4). S139–S140. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact